Impact of Pain and Symptom Burden on the Health-Related Quality of Life of Hemodialysis Patients

Journal of Pain and Symptom Management

Volumn 39, Issue 3, 2010, Pages 477-485

  Davison, Sara N ^a   Jhangri, Gian S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

dialysis; end stage renal disease; Pain; quality of life; symptom burden

Indexed keywords

BIOCHEMICAL MARKER; CALCIUM; HEMOGLOBIN; PHOSPHORUS; SERUM ALBUMIN;

ADULT; ANOREXIA; ANXIETY; ARTICLE; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DEPRESSION; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PAIN; PERITONEAL DIALYSIS; PREDICTOR VARIABLE; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SYMPTOM; WELLBEING;

AGED; COST OF ILLNESS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PAIN; QUALITY OF LIFE; RENAL DIALYSIS;

EID: 77949475046     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2009.08.008     Document Type: Article

References (48)

1. Kimmel P.L., Peterson R.A., Weihs K.L., et al. Aspects of quality of life in hemodialysis patients. J Am Soc Nephrol 6 (1995) 1418-1426
2. Fainsinger R., Davison S.N., and Brenneis C. A supportive care model for dialysis patients. Palliat Med 17 (2003) 81-82
3. Davison S.N. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis 42 (2003) 1239-1247
4. Davison S.N., Jhangri G.S., and Johnson J.A. Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int 69 (2006) 1621-1625
5. Davison S.N., Jhangri G.S., and Johnson J.A. Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients. Nephrol Dial Transplant 21 (2006) 3189-3195
6. Murtagh F.E., Addington-Hall J.M., Donohoe P., and Higginson I.J. Symptom management in patients with established renal failure managed without dialysis. EDTNA ERCA J 32 2 (2006) 93-98
7. Murtagh F.E., Addington-Hall J., and Higginson I.J. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 14 (2007) 82-99
8. Saini T., Murtagh F.E., Dupont P.J., et al. Comparative pilot study of symptoms and quality of life in cancer patients and patients with end stage renal disease. Palliat Med 20 (2006) 631-636
9. Solano J.P., Gomes B., and Higginson I.J. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 31 (2006) 58-69
10. Davison S.N., and Jhangri G.S. The impact of chronic pain on depression, sleep, and the desire to withdraw from dialysis in hemodialysis patients. J Pain Symptom Manage 30 (2005) 465-473
11. O'Donnell K., and Chung J.Y. The diagnosis of major depression in end-stage renal disease. Psychother Psychosom 66 (1997) 38-43
12. Smith M.D., Hong B.A., and Robson A.M. Diagnosis of depression in patients with end-stage renal disease. Comparative analysis. Am J Med 79 (1985) 160-166
13. Weisbord S.D., Fried L.F., Mor M.K., et al. Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol 2 (2007) 960-967
14. Paniagua R., Amato D., Vonesh E., et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13 (2002) 1307-1320
15. Eknoyan G., Beck G.J., Cheung A.K., et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 (2002) 2010-2019
16. DeOreo P.B. The use of patient-based instruments to measure, manage, and improve quality of care in dialysis facilities. Adv Ren Replace Ther 8 (2001) 125-130
17. Ifudu O., Paul H.R., Homel P., and Friedman E.A. Predictive value of functional status for mortality in patients on maintenance hemodialysis. Am J Nephrol 18 (1998) 109-116
18. McClellan W.M., Anson C.A., Birkeli K., and Tuttle E. Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease. J Clin Epidemiol 44 (1991) 83-89
19. Chang V.T., Hwang S.S., and Kasimis B. Longitudinal documentation of cancer pain management outcomes: a pilot study at a VA medical center. J Pain Symptom Manage 24 (2002) 494-505
20. Vogl D., Rosenfeld B., Breitbart W., et al. Symptom prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage 18 (1999) 253-262
21. Cameron J.I., Whiteside C., Katz J., and Devins G.M. Differences in quality of life across renal replacement therapies: a meta-analytic comparison. Am J Kidney Dis 35 (2000) 629-637
22. Kimmel P.L., Emont S.L., Newmann J.M., Danko H., and Moss A.H. ESRD patient quality of life: symptoms, spiritual beliefs, psychosocial factors, and ethnicity. Am J Kidney Dis 42 (2003) 713-721
23. Patel S.S., Shah V.S., Peterson R.A., and Kimmel P.L. Psychosocial variables, quality of life, and religious beliefs in ESRD patients treated with hemodialysis. Am J Kidney Dis 40 (2002) 1013-1022
24. Weisbord S.D., Fried L.F., Arnold R.M., et al. Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol 16 (2005) 2487-2494
25. Curtin R.B., Bultman D.C., Thomas-Hawkins C., Walters B.A., and Schatell D. Hemodialysis patients' symptom experiences: effects on physical and mental functioning. 562, 567-572, 574. Nephrol Nurs J 29 (2002)
26. Hays R.D., Kallich J.D., Mapes D.L., et al. Kidney Disease Quality of Life Short Form (KDQOL-SF), Version 1.3: a manual for use and scoring. Qual Life Res 3 (1994) 329-338
27. Hays R.D. RAND 36 health status inventory (1998), Harcourt Brace & Company, New York
28. Ware Jr. J.E., Kosinski M., and Keller S.D. A 12-time short form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 34 (1996) 220-233
29. Birbeck G.L., Kim S., Hays R.D., and Vickrey B.G. Quality of life measures in epilepsy: how well can they detect change over time?. Neurology 54 (2000) 1822-1827
30. Johnson J.A., and Maddigan S.L. Performance of the RAND-12 and SF-12 summary scores in type 2 diabetes. Qual Life Res 13 (2004) 449-456
31. Nortvedt M.W., Riise T., Myhr K.M., and Nyland H.I. Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care 38 (2000) 1022-1028
32. Taft C., Karlsson J., and Sullivan M. Do SF-36 summary component scores accurately summarize subscale scores?. Qual Life Res 10 (2001) 395-404
33. Beddhu S., Bruns F.J., Saul M., Seddon P., and Zeidel M.L. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 108 (2000) 609-613
34. Weisbord S.D., Carmody S.S., Bruns F.J., et al. Symptom burden, quality of life, advance care planning and the potential value of palliative care in severely ill haemodialysis patients. Nephrol Dial Transplant 18 (2003) 1345-1352
35. Weisbord S.D., and Kimmel P.L. Health-related quality of life in the era of erythropoietin. Hemodial Int 12 (2008) 6-15
36. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300 (1990) 573-578
37. Parfrey P.S., Foley R.N., Wittreich B.H., et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 (2005) 2180-2189
38. Levin N.W., Lazarus J.M., and Nissenson A.R. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure-an interim report. The National Cooperative rHu Erythropoietin Study Group. Am J Kidney Dis 22 2 Suppl 1 (1993) 3-12
39. Beusterien K.M., Nissenson A.R., Port F.K., et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 7 (1996) 763-773
40. Moreno F., Sanz-Guajardo D., Lopez-Gomez J.M., Jofre R., and Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 11 (2000) 335-342
41. Furuland H., Linde T., Ahlmen J., et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18 (2003) 353-361
42. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
43. Laupacis A., Wong C., and Churchill D. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group. Control Clin Trials 12 Suppl 4 (1991) 168S-179S
44. Plantinga L.C., Fink N.E., Jaar B.G., et al. Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis. Qual Life Res 16 (2007) 755-765
45. Unruh M., Benz R., Greene T., et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int 66 (2004) 355-366
46. U.S. Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. USRDS 2007 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States (2007), USRDS, Bethesda, MD
47. Canadian Institute for Health Information. 2007 annual report-treatment of end-stage organ failure in Canada 1996 to 2005 (2008), CIHI, Ottawa, Ontario, Canada
48. Davison S.N., Murtagh F.E.M., and Higginson I.J. Methodological considerations for end-of life research in patients with chronic kidney disease. J Nephrol 21 (2008) 268-282